crest                

 

CHL 5225 H -- ADVANCED STATISTICAL METHODS FOR CLINICAL TRIALS



 

Cost-effectiveness Analysis



Required Reading:

  1. Willan AR, Briggs AH. The Statistical Analysis of Cost-effectiveness Data. Chichester UK: Wiley 2006. (Chapters 1, 4 & Sections 5.1,5.2 and 5.3) Download

  2. Willan AR, Incremental net benefit in the analysis of economic data from clinical trials with application to the CADET-Hp Trial. European Journal of Gastroenterology and Hepatology 2004; 16:543-549. Download



References:

  1. Meltzer MI. Introduction to health economics for physicians. Lancet 2001; 358: 993-998.

  2. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Economics 2004; 13: 461-475.

  3. Grieve R, Nixon R, Thompson SG, Normand C. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Economics 2005; 14: 185-196.

  4. Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. Health Economics 2005; 14: 471-475.

  5. Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Economics 2005; 14: (early view).

  6. Pinto EM, Willan AR, O’Brien BJ. Cost-effectiveness analysis for multinational clinical trials. Statistics in Medicine 2005; 24:1965-1982.

  7. Thompson SG, Warn DE, Turner RM. Bayesian methods for analysis of binary outcome data in cluster randomized trials on the absolute risk scale. Statistics in Medicine 2004 23: 389-410.

  8. Willan AR, O'Brien BJ. Cost prediction models for the comparison of two groups. Health Economics 2001; 10:363-366.

  9. Willan AR, Analysis, sample size and power for estimating incremental net health benefit from clinical trial data. Control Clinical Trials 2001; 22:228-237.

  10. Willan AR, O'Brien BJ, Leyva RA. Cost-effectiveness analysis when the WTA is greater than the WTP. Statistics in Medicine 2001; 20:3251-3259.

  11. Willan AR, Lin DY, Cook RJ, Chen EB. Using inverse-weighting in cost-effectiveness analysis with censored data. Statistical Methods in Medical Research 2002; 11:539-551.

  12. Willan AR, Chen EB, Cook RJ, Lin DY. Incremental net benefit in randomized clinical trials with qualify-adjusted survival. Statistics in Medicine 2003; 22:353-362.

  13. Willan AR, Lin DY, Manca A. Regression methods for cost-effectiveness analysis with censored data. Statistics in Medicine. 2005; 24:131-145.

  14. Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Statistics in Medicine 2001; 20:1563-1574.

  15. Willan AR, Pinto EM, O’Brien BJ, Kaul P, Goeree R, Lynd L, Armstrong PW. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Economics 2005; 14: 327-338.

  16. Willan AR, Briggs AH. The Statistical Analysis of Cost-effectiveness Data 2006; New York: John Wiley & Sons. Chapter 3 and Section 6.5.


Class Notes